| 000 | 01519 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514014755.0 | ||
| 264 | 0 | _c20011204 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a0093-7754 | ||
| 024 | 7 |
_a10.1016/s0093-7754(01)90152-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTaplin, M E | |
| 245 | 0 | 0 |
_aDocetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer. _h[electronic resource] |
| 260 |
_bSeminars in oncology _cAug 2001 |
||
| 300 |
_a32-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xblood |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 |
_aEstramustine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xblood |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 | _aTaxoids |
| 700 | 1 | _aBubley, G J | |
| 700 | 1 | _aRajeshkumar, B | |
| 700 | 1 | _aShuster, T | |
| 700 | 1 | _aKo, Y J | |
| 700 | 1 | _aMorganstern, D E | |
| 773 | 0 |
_tSeminars in oncology _gvol. 28 _gno. 4 Suppl 15 _gp. 32-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0093-7754(01)90152-6 _zAvailable from publisher's website |
| 999 |
_c11602477 _d11602477 |
||